Download PDF
Fortschr Neurol Psychiatr 2002; 70(7): 339-352
DOI: 10.1055/s-2002-32517
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Antikonvulsive Pharmakotherapie: Entwicklung in den letzten 10 Jahren

Pharmacological Treatment of Epilepsies: Progress During the Last 10 YearsH.  Stefan1 , C.  Tilz1
  • 1Neurologische Klinik, Universität Erlangen-Nürnberg (Direktor: Prof. Dr. B. Neundörfer)
Further Information

Publication History

Publication Date:
28 June 2002 (online)

    Permissions and Reprints

Zusammenfassung

Die medikamentöse Behandlung von Epilepsien ist ein Schwerpunktgebiet der Neurologie, das nicht nur in spezialisierten Zentren von Bedeutung ist, sondern auch von niedergelassenen Kollegen häufige und wichtige therapeutische Entscheidungen erfordert. Die Wahl des richtigen Antikonvulsivums ist nicht immer einfach zu treffen, da sich die Möglichkeiten durch die Neuentwicklung zahlreicher Substanzen in den letzten 10 Jahren sehr erweitert haben. Dadurch ergeben sich neue Therapiestrategien, die eine differenziertere Einzeltherapie ermöglichen, als es durch die bisher verhältnismäßig wenigen am Markt zugelassenen Substanzen möglich war. Die neuen Substanzen zeichnen sich insgesamt durch bessere Verträglichkeit und geringere Nebenwirkungen aus, allerdings ist eine genauere Kenntnis der Wirkungs- und Nebenwirkungsprofile erforderlich. Die Pharmakologie, Pharmakokinetik, Indikation, Dosierung und Nebenwirkungen der einzelnen Substanzen werden kurz zusammengefasst diskutiert.

Abstract

The pharmacological treatment of epilepsies represents an important domain of neurological therapeutical strategies and is not only important for specialized epilepsy centres, but for all hospital -and office-based neurologists. The choice of the right anticonvulsive drug is not always simple since the development of new drugs during the last 10 years offers a broad range of possibilities. Therefore, pharmacological treatment has become more sophisticated than it was with relatively few anticonvulsive drugs before. The new drugs are better tolerated and have less side effects, but more knowledge is required about the specific aspects of each drug. Pharmacology, pharmacocinetics, indication, dosage and side effects of the substances will be summarized and discussed.

Literatur

  • 1 Meldrum B S. GABAergic mechanisms in the pathogenesis and treatment of epilepsy.  Br J Clin Pharmacol. 1989;  27 Suppl 1 S3-S11
    PubMedGoogle Scholar
  • 2 Petroff O A, Rothman D L, Behar K L, Collins T L, Mattson R H. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy.  Neurology. 1996;  47 1567-1571
    PubMedGoogle Scholar
  • 3 During M J, Spencer D D. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain [see comments].  Lancet. 1993;  341 1607-1610
    CrossrefPubMedGoogle Scholar
  • 4 Petroff O A, Rothman D L, Behar K L, Mattson R H. Low brain GABA level is associated with poor seizure control.  Ann Neurol. 1996;  40 908-911
    CrossrefPubMedGoogle Scholar
  • 5 Petroff O A, Rothman D L, Behar K L, Mattson R H. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose.  Neurology. 1996;  46 1459-1463
    PubMedGoogle Scholar
  • 6 Petroff O A, Rothman D L. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.  Mol Neurobiol. 1998;  16 97-121
    PubMedGoogle Scholar
  • 7 Mattson R H, Petroff O, Rothman D, Behar K. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy.  Epilepsia. 1994;  35 Suppl 5 S29-S32
    PubMedGoogle Scholar
  • 8 Halonen T, Lehtinen M, Pitkanen A, Ylinen A, Riekkinen P J. Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin).  Epilepsy Res. 1988;  2 246-252
    CrossrefPubMedGoogle Scholar
  • 9 Elwes R D, Binnie C D. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.  Clin Pharmacokinet. 1996;  30 403-415
    PubMedGoogle Scholar
  • 10 Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.  Clin Pharmacokinet . 1995;  29 341-369
    PubMedGoogle Scholar
  • 11 Jacqz-Aigrain E, Guillonneau M, Rey E, Macher M A, Montes C, Chiron C, Loirat C. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.  Br J Clin Pharmacol. 1997;  44 183-185
    CrossrefPubMedGoogle Scholar
  • 12 Hoke J F, Yuh L, Antony K K, Okerholm R A, Elberfeld J M, Sussman N M. Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers.  J Clin Pharmacol. 1993;  33 458-462
    PubMedGoogle Scholar
  • 13 Durham S L, Hoke J F, Chen T M. Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers.  Drug Metab Dispos. 1993;  21 480-484
    PubMedGoogle Scholar
  • 14 Rimmer E M, Richens A. Interaction between vigabatrin and phenytoin.  Br J Clin Pharmacol. 1989;  27 Suppl 1 27S-33S
    PubMedGoogle Scholar
  • 15 Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.  Seizure. 2000;  9 224-232
    CrossrefPubMedGoogle Scholar
  • 16 Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.  Lancet. 1999;  354 13-19
    CrossrefPubMedGoogle Scholar
  • 17 Gobbi G, Pini A, Bertani G, Menegati E, Tiberti A, Valseriati D, Besana D, Rasmini P, Guerrini R, Belmonte A, Veggiotti P, Resi C, Lanzi G, Capovilla G, Galeone D, Milani S. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies.  Epilepsy Res. 1999;  35 29-37
    CrossrefPubMedGoogle Scholar
  • 18 Granstrom M L, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.  Epilepsia. 1999;  40 950-957
    PubMedGoogle Scholar
  • 19 Zahner B, Stefan H, Blankenhorn V, Kramer G, Richens A, Thumler R, Mumford J P. Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study.  Epilepsia. 1999;  40 311-315
    PubMedGoogle Scholar
  • 20 Aicardi J, Mumford J P, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.  Epilepsia. 1996;  37 638-642
    CrossrefPubMedGoogle Scholar
  • 21 Russell-Eggitt I M, Mackey D A, Taylor D S, Timms C, Walker J W. Vigabatrin-associated visual field defects in children.  Eye. 2000;  14 9
    PubMedGoogle Scholar
  • 22 Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.  Seizure. 2000;  9 112-118
    CrossrefPubMedGoogle Scholar
  • 23 Comaish I F, Gorman C, Galloway N R. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.  BMJ. 2000;  320 1403
    CrossrefPubMedGoogle Scholar
  • 24 Hardus P, Verduin W M, Postma G, Stilma J S, Berendschot T T, van-Veelen C W. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.  Epilepsia. 2000;  41 581-587
    PubMedGoogle Scholar
  • 25 Wild J M, Martinez C, Reinshagen G, Harding G F. Characteristics of a unique visual field defect attributed to vigabatrin.  Epilepsia. 1999;  40 1784-1794
    PubMedGoogle Scholar
  • 26 Lawden M C, Eke T, Degg C, Harding G F, Wild J M. Visual field defects associated with vigabatrin therapy.  J Neurol Neurosurg Psychiatry. 1999;  67 716-722
    CrossrefPubMedGoogle Scholar
  • 27 Acheson J F. Vigabatrin associated visual field constriction.  J Neurol Neurosurg Psychiatry. 1999;  67 707-708
    PubMedGoogle Scholar
  • 28 Wilton L V, Stephens M D, Mann R D. Visual field defect associated with vigabatrin: observational cohort study.  BMJ. 1999;  319 1165-1166
    PubMedGoogle Scholar
  • 29 Panayiotopoulos C P, Agathonikou A, Sharoqi I A, Parker A P. Vigabatrin aggravates absences and absence status.  Neurology. 1997;  49 1467
    PubMedGoogle Scholar
  • 30 Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin [letter; comment].  BMJ. 1998;  316 233
    PubMedGoogle Scholar
  • 31 Eke T, Talbot J F, Lawden M C. Severe persistent visual field constriction associated with vigabatrin [see comments].  BMJ. 1997;  314 180-181
    PubMedGoogle Scholar
  • 32 Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.  Neurology. 1999;  53 922-926
    PubMedGoogle Scholar
  • 33 Krauss G L, Johnson M A, Miller N R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings [see comments].  Neurology. 1998;  50 614-618
    CrossrefPubMedGoogle Scholar
  • 34 Stefan H, Bernatik J, Knorr J. Gesichtsfeldstörungen bei Antiepileptikabehandlung. [Visual field defects due to antiepileptic drugs].  Nervenarzt. 1999;  70 552-555
    CrossrefPubMedGoogle Scholar
  • 35 Levinson D F, Devinsky O. Psychiatric adverse events during vigabatrin therapy.  Neurology. 1999;  53 1503-1511
    PubMedGoogle Scholar
  • 36 Buckland P R, Spurlock G, McGuffin P. Amphetamine and vigabatrin down regulate aromatic L-amino acid decarboxylase mRNA levels.  Brain Res Mol Brain Res. 1996;  35 69-76
    PubMedGoogle Scholar
  • 37 Canovas-Martinez A, Ordovas-Baines J P, Beltran-Marques M, Escriva-Aparisi A, Delgado-Cordon F. Vigabatrin-associated reversible acute psychosis in a child.  Ann Pharmacother. 1995;  29 1115-1117
    PubMedGoogle Scholar
  • 38 Jawad S, Clarke E, Richens A. Vigabatrin-induced psychosis - management problems.  Seizure. 1994;  3 309-310
    PubMedGoogle Scholar
  • 39 Naumann M, Supprian T, Kornhuber J, Lange K W, Reiners K. Bipolar affective psychosis after vigabatrin.  Lancet. 1994;  343 606-607
    CrossrefPubMedGoogle Scholar
  • 40 Srinivasan J, Richens A. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.  Drug Saf. 1994;  10 395-405
    PubMedGoogle Scholar
  • 41 Staples C I, King M A, Boyle R S. Acute psychosis after withdrawal of vigabatrin.  Med J Aust. 1992;  156 291
    PubMedGoogle Scholar
  • 42 Sander J W, Hart Y M, Trimble M R, Shorvon S D. Vigabatrin and psychosis.  J Neurol Neurosurg Psychiatry. 1991;  54 435-439
    CrossrefPubMedGoogle Scholar
  • 43 Guberman A. Vigabatrin.  Can J Neurol Sci. 1996;  23 S13-S17
    PubMedGoogle Scholar
  • 44 Veggiotti P, de Agostini G, Muzio C, Termine C, Baldi P L, Ferrari-Ginevra O, Lanzi G. Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study.  Acta Neurol Scand. 1999;  99 142-146
    CrossrefPubMedGoogle Scholar
  • 45 Matsuo F, Gay P, Madsen J, Tolman K G, Rollins D E, Risner M E, Lai A A. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. 1996
    Google Scholar
  • 46 Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics.  Clin Pharmacokinet. 1993;  25 433-443
    PubMedGoogle Scholar
  • 47 Wang S J, Huang C C, Hsu K S, Tsai J J, Gean P W. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons.  Synapse. 1996;  24 248-255
    CrossrefPubMedGoogle Scholar
  • 48 Wang S J, Huang C C, Hsu K S, Tsai J J, Gean P W. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones.  Neuroreport. 1996;  7 3037-3040
    PubMedGoogle Scholar
  • 49 Xie X, Hagan R M. Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.  Neuropsychobiology. 1998;  38 119-130
    PubMedGoogle Scholar
  • 50 Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications.  Eur J Pharmacol. 1996;  307 113-116
    CrossrefPubMedGoogle Scholar
  • 51 Richens A. Safety of lamotrigine.  Epilepsia. 1994;  35 Suppl 5 S37-S40
    PubMedGoogle Scholar
  • 52 Pisani F, Oteri G, Russo M F, Di-Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.  Epilepsia. 1999;  40 1141-1146
    CrossrefPubMedGoogle Scholar
  • 53 May T W, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.  Ther Drug Monit. 1999;  21 175-181
    CrossrefPubMedGoogle Scholar
  • 54 May T W, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.  Ther Drug Monit. 1996;  18 523-531
    CrossrefPubMedGoogle Scholar
  • 55 Kanner A M, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. 2000
    Google Scholar
  • 56 Gericke C A, Picard F, de-Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. 1999
    Google Scholar
  • 57 Manganotti P, Bongiovanni L G, Zanette G, Turazzini M, Fiaschi A. Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. 1999
    Google Scholar
  • 58 Brodie M J, Overstall P W, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. 1999
    Google Scholar
  • 59 Frank L M, Enlow T, Holmes G L, Manasco P, Concannon S, Chen C, Womble G, Casale E J. Lamictal (lamotrigine) monotherapy for typical absence seizures in children.  Epilepsia. 1999;  40 973-979
    PubMedGoogle Scholar
  • 60 Beran R G, Berkovic S F, Dunagan F M, Vajda F J, Danta G, Black A B, Mackenzie R. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. 1998
    Google Scholar
  • 61 Shuaib A, Mahmood R H, Wishart T, Kanthan R, Murabit M A, Ijaz S, Miyashita H, Howlett W. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study.  Brain Res. 1995;  702 199-206
    CrossrefPubMedGoogle Scholar
  • 62 Siniscalchi A, Zona C, Guatteo E, Mercuri N B, Bernardi G. An electrophysiological analysis of the protective effects of felbamate, lamotrigine, and lidocaine on the functional recovery from in vitro ischemia in rat neocortical slices.  Synapse. 1998;  30 371-379
    CrossrefPubMedGoogle Scholar
  • 63 Crumrine R C, Bergstrand K, Cooper A T, Faison W L, Cooper B R. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest.  Stroke. 1997;  28 2230-2236
    PubMedGoogle Scholar
  • 64 Zipp F, Baas H, Fischer P A. Lamotrigine-antiparkinsonian activity by blockade of glutamate release?.  J Neural Transm Park Dis Dement Sect. 1993;  5 67-75
    PubMedGoogle Scholar
  • 65 Messenheimer J A. Rash in adult and pediatric patients treated with lamotrigine.  Can J Neurol Sci. 1998;  25 S14-S18
    PubMedGoogle Scholar
  • 66 Messenheimer J A, Guberman A H. Rash with lamotrigine: dosing guidelines [letter].  Epilepsia. 2000;  41 488
    PubMedGoogle Scholar
  • 67 Farrell K, Connolly M B, Munn R, Peng S, MacWilliam L M. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. 1997
    Google Scholar
  • 68 Kilpatrick E S, Forrest G, Brodie M J. Concentration - effect and concentration - toxicity relations with lamotrigine: a prospective study. 1996
    Google Scholar
  • 69 Ramsay R E, Pellock J M, Garnett W R, Sanchez R M, Valakas A M, Wargin W A, Lai A A, Hubbell J, Chern W H, Allsup T. et al . Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy.  Epilepsy Res. 1991;  10 191-200
    CrossrefPubMedGoogle Scholar
  • 70 Verma A, Miller P, Carwile S T, Husain A M, Radtke R A. Lamotrigine-induced blepharospasm.  Pharmacotherapy. 1999;  19 877-880
    CrossrefPubMedGoogle Scholar
  • 71 Rambeck B, Kurlemann G, Stodieck S R, May T W, Jurgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child.  Eur J Clin Pharmacol. 1997;  51 481-484
    CrossrefPubMedGoogle Scholar
  • 72 Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.  Neuropediatrics. 1994;  25 284-289
    PubMedGoogle Scholar
  • 73 Sadler M. Lamotrigine associated with insomnia.  Epilepsia. 1999;  40 322-325
    PubMedGoogle Scholar
  • 74 Rho J M, Donevan S D, Rogawski M A. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors.  Ann Neurol. 1994;  35 229-234
    CrossrefPubMedGoogle Scholar
  • 75 Pellock J M. Felbamate.  Epilepsia. 1999;  40 Suppl 5 57-62
    PubMedGoogle Scholar
  • 76 Stefan H. Epilepsien: Diagnose und Behandlung. Stuttgart: Georg Thieme Verlag 1999
    Google Scholar
  • 77 Glue P, Banfield C R, Perhach J L, Mather G G, Racha J K, Levy R H. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.  Clin Pharmacokinet. 1997;  33 214-224
    PubMedGoogle Scholar
  • 78 Richens A, Banfield C R, Salfi M, Nomeir A, Lin C C, Jensen P, Affrime M B, Glue P. Single and multiple dose pharmacokinetics of felbamate in the elderly.  Br J Clin Pharmacol. 1997;  44 129-134
    CrossrefPubMedGoogle Scholar
  • 79 Glue P, Sulowicz W, Colucci R, Banfield C, Pai S, Lin C, Affrime M B. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction.  Br J Clin Pharmacol. 1997;  44 91-93
    CrossrefPubMedGoogle Scholar
  • 80 Sachdeo R, Wagner M L, Sachdeo S, Shumaker R C, Lyness W H, Rosenberg A, Ward D, Perhach J L. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.  Epilepsia. 1999;  40 1122-1128
    PubMedGoogle Scholar
  • 81 Sachdeo R C, Narang-Sachdeo S, Montgomery P A, Shumaker R C, Perhach J L, Lyness W H, Rosenberg A. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.  J Clin Pharmacol. 1998;  38 184-190
    PubMedGoogle Scholar
  • 82 Contin M, Riva R, Albani F, Baruzzi A A. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.  Ther Drug Monit. 1999;  21 604-608
    CrossrefPubMedGoogle Scholar
  • 83 Marciani M G, Spanedda F, Placidi F, Bassetti M A, Romigi A, Mattia D. Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.  Int J Neurosci. 1998;  95 247-253
    PubMedGoogle Scholar
  • 84 Siegel H, Kelley K, Stertz B, Reeves-Tyer P, Flamini R, Malow B, Gaillard W D, Ko D, Theodore W H. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome.  Epilepsy Res. 1999;  34 91-97
    CrossrefPubMedGoogle Scholar
  • 85 Lian H, Steiner S S, Sofia R D, Woodhead J H, Wolf H H, White H S, Shen G S, Rhodes C A, McCabe R T. A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate.  J Pharm Sci. 2000;  89 867-875
    CrossrefPubMedGoogle Scholar
  • 86 Kaufman D W, Kelly J P, Anderson T, Harmon D C, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate.  Epilepsia. 1997;  38 1265-1269
    PubMedGoogle Scholar
  • 87 Pellock J M. Felbamate in epilepsy therapy: evaluating the risks.  Drug Saf. 1999;  21 225-239
    PubMedGoogle Scholar
  • 88 Kerrick J M, Kelley B J, Maister B H, Graves N M, Leppik I E. Involuntary movement disorders associated with felbamate.  Neurology. 1995;  45 185-187
    PubMedGoogle Scholar
  • 89 Taylor C P. Mechanisms of action of gabapentin.  Rev Neurol Paris. 1997;  153 Suppl 1 S39-S45
    PubMedGoogle Scholar
  • 90 Taylor C P, Gee N S, Su T Z, Kocsis J D, Welty D F, Brown J P, Dooley D J, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology.  Epilepsy Res. 1998;  29 233-249
    CrossrefPubMedGoogle Scholar
  • 91 Gidal B E, Maly M M, Budde J, Lensmeyer G L, Pitterle M E, Jones J C. Effect of a high-protein meal on gabapentin pharmacokinetics.  Epilepsy Res. 1996;  23 71-76
    CrossrefPubMedGoogle Scholar
  • 92 Petroff O A, Hyder F, Rothman D L, Mattson R H. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.  Epilepsia. 2000;  41 675-680
    PubMedGoogle Scholar
  • 93 Goldlust A, Su T Z, Welty D F, Taylor C P, Oxender D L. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA.  Epilepsy Res. 1995;  22 1-11
    CrossrefPubMedGoogle Scholar
  • 94 Wamil A W, McLean M J. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture.  Epilepsy Res. 1994;  17 1-11
    CrossrefPubMedGoogle Scholar
  • 95 Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons.  Neuropharmacology. 1998;  37 83-91
    CrossrefPubMedGoogle Scholar
  • 96 Rao M L, Clarenbach P, Vahlensieck M, Kratzschmar S. Gabapentin augments whole blood serotonin in healthy young men.  J Neural Transm. 1988;  73 129-134
    CrossrefPubMedGoogle Scholar
  • 97 Thurlow R J, Hill D R, Woodruff G N. Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain.  Br J Pharmacol. 1996;  118 457-465
    PubMedGoogle Scholar
  • 98 Hetherington H P, Newcomer B R, Pan J W. Measurements of human cerebral GABA at 4.1 T using numerically optimized editing pulses.  Magn Reson Med. 1998;  39 6-10
    PubMedGoogle Scholar
  • 99 Radulovic L L, Turck D, von-Hodenberg A, Vollmer K O, McNally W P, DeHart P D, Hanson B J, Bockbrader H N, Chang T. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.  Drug Metab Dispos. 1995;  23 441-448
    PubMedGoogle Scholar
  • 100 Gidal B E, Maly M M, Kowalski J W, Rutecki P A, Pitterle M E, Cook D E. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition.  Ann Pharmacother. 1998;  32 405-409
    PubMedGoogle Scholar
  • 101 Vollmer K O, von-Hodenberg A, Kolle E U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man.  Arzneimittelforschung. 1986;  36 830-839
    PubMedGoogle Scholar
  • 102 Blum R A, Comstock T J, Sica D A, Schultz R W, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch J A, Reece P A. et al . Pharmacokinetics of gabapentin in subjects with various degrees of renal function.  Clin Pharmacol Ther. 1994;  56 154-159
    CrossrefPubMedGoogle Scholar
  • 103 Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group.  Epilepsia. 1999;  40 1147-1154
    PubMedGoogle Scholar
  • 104 Leiderman D B. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials.  Epilepsia. 1994;  35 Suppl 5 S74-S76
    PubMedGoogle Scholar
  • 105 Anhut H, Ashman P, Feuerstein T J, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group.  Epilepsia. 1994;  35 795-801
    CrossrefPubMedGoogle Scholar
  • 106 Anonym . Gabapentin in partial epilepsy. UK Gabapentin Study Group.  Lancet. 1990;  335 1114-1117
    CrossrefPubMedGoogle Scholar
  • 107 Vossler D G. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin.  Neurology. 1996;  46 852-853
    PubMedGoogle Scholar
  • 108 Chadwick D, Leiderman D B, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalized seizures.  Epilepsy Res. 1996;  25 191-197
    CrossrefPubMedGoogle Scholar
  • 109 Laird M A, Gidal B E. Use of gabapentin in the treatment of neuropathic pain.  Ann Pharmacother. 2000;  34 802-807
    CrossrefPubMedGoogle Scholar
  • 110 Field M J, Oles R J, Lewis A S, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents.  Br J Pharmacol. 1997;  121 1513-1522
    CrossrefPubMedGoogle Scholar
  • 111 Houtchens M K, Richert J R, Sami A, Rose J W. Open label gabapentin treatment for pain in multiple sclerosis.  Mult Scler. 1997;  3 250-253
    PubMedGoogle Scholar
  • 112 Gironell A, Kulisevsky J, Barbanoj M, Lopez V D, Hernandez G, Pascual S B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor.  Arch Neurol. 1999;  56 475-480
    CrossrefPubMedGoogle Scholar
  • 113 Kothare S V, Pollack P, Kulberg A G, Ravin P D. Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus.  Pediatr Neurol. 2000;  22 68-71
    CrossrefPubMedGoogle Scholar
  • 114 Evidente V G, Adler C H, Caviness J N, Gwinn K A. Effective treatment of orthostatic tremor with gabapentin.  Mov Disord. 1998;  13 829-831
    CrossrefPubMedGoogle Scholar
  • 115 Steinhoff B J, Herrendorf G, Bittermann H J, Kurth C. Isolated ataxia as an idiosyncratic side-effect under gabapentin.  Seizure. 1997;  6 503-504
    CrossrefPubMedGoogle Scholar
  • 116 Adler C H. Treatment of restless legs syndrome with gabapentin.  Clin Neuropharmacol. 1997;  20 148-151
    PubMedGoogle Scholar
  • 117 Tusa R J. Nystagmus: diagnostic and therapeutic strategies.  Semin Ophthalmol. 1999;  14 65-73
    PubMedGoogle Scholar
  • 118 Gottlob I. Nystagmus.  Curr Opin Ophthalmol. 1998;  9 32-38
    PubMedGoogle Scholar
  • 119 Kori A A, Robin N H, Jacobs J B, Erchul D M, Zaidat O O, Remler B F, Averbuch-Heller L, Dell'Osso L F, Leigh R J, Zinn A B. Pendular nystagmus in patients with peroxisomal assembly disorder.  Arch Neurol. 1998;  55 554-558
    CrossrefPubMedGoogle Scholar
  • 120 Averbuch-Heller L, Tusa R J, Fuhry L, Rottach K G, Ganser G L, Heide W, Buttner U, Leigh R J. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus.  Ann Neurol. 1997;  41 818-825
    CrossrefPubMedGoogle Scholar
  • 121 Averbuch-Heller L, Leigh R J. Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies.  Aust N Z J Ophthalmol. 1997;  25 7-13
    PubMedGoogle Scholar
  • 122 Anonymous . The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group.  Epilepsy Res. 1994;  18 67-73
    CrossrefPubMedGoogle Scholar
  • 123 McLean M J. Gabapentin in the management of convulsive disorders.  Epilepsia. 1999;  40 Suppl 6 S39-S50, discussion S73 - S74
    CrossrefPubMedGoogle Scholar
  • 124 Gidal B E, Maly M M, Nemire R E, Haley K. Weight gain and gabapentin therapy [letter].  Ann Pharmacother. 1995;  29 1048
    PubMedGoogle Scholar
  • 125 Wong I C, Lhatoo S D. Adverse reactions to new anticonvulsant drugs.  Drug Saf. 2000;  23 35-56
    PubMedGoogle Scholar
  • 126 Reeves A L, So E L, Sharbrough F W, Krahn L E. Movement disorders associated with the use of gabapentin.  Epilepsia. 1996;  37 988-990
    PubMedGoogle Scholar
  • 127 Betts T. Neurontin - 1 year on. London October 1994.  Seizure. 1995;  4 1-4
    PubMedGoogle Scholar
  • 128 Bruni J. Gabapentin.  Can J Neurol Sci. 1996;  23 S10-S12
    PubMedGoogle Scholar
  • 129 Meldrum B S, Chapman A G. Basic mechanisms of gabitril (tiagabine) and future potential developments.  Epilepsia. 1999;  40 Suppl 9 S2-S6
    PubMedGoogle Scholar
  • 130 Soudijn W, van W I. The GABA transporter and its inhibitors.  Curr Med Chem. 2000;  7 1063-1079
    CrossrefPubMedGoogle Scholar
  • 131 Krogsgaard L P, Frolund B, Frydenvang K. GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects.  Curr Pharm Des. 2000;  6 1193-1209
    CrossrefPubMedGoogle Scholar
  • 132 Anonym[symbol see text] . Tiagabine: add-on treatment for partial seizures.  Drug Ther Bull. 2000;  38 47-48
    PubMedGoogle Scholar
  • 133 Schachter S C. Tiagabine.  Epilepsia. 1999;  40 Suppl 5 S17-S22
    PubMedGoogle Scholar
  • 134 Gatti G, Bonomi I, Jannuzzi G, Perucca E. The new antiepileptic drugs: pharmacological and clinical aspects.  Curr Pharm Des. 2000;  6 839-860
    CrossrefPubMedGoogle Scholar
  • 135 Ramsay R E, Pryor F. Epilepsy in the elderly.  Neurology. 2000;  55 S9-S14
    PubMedGoogle Scholar
  • 136 Loiseau P. Review of controlled trials of gabitril (tiagabine): a clinician’s viewpoint.  Epilepsia. 1999;  40 Suppl 9 S14-S19
    PubMedGoogle Scholar
  • 137 Schaffer L C, Schaffer C B. Tiagabine and the treatment of refractory bipolar disorder [letter].  Am J Psychiatry. 1999;  156 2014-2015
    PubMedGoogle Scholar
  • 138 Trimble M R, Rusch N, Betts T, Crawford P M. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables.  Seizure. 2000;  9 249-254
    CrossrefPubMedGoogle Scholar
  • 139 Holden K R, Titus M O. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study.  Pediatr Neurol. 1999;  21 728-730
    CrossrefPubMedGoogle Scholar
  • 140 Knake S, Hamer H M, Schomburg U, Oertel W H, Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy.  Seizure. 1999;  8 314-317
    CrossrefPubMedGoogle Scholar
  • 141 Trinka E, Moroder T, Nagler M, Staffen W, Loscher W, Ladurner G. Clinical and EEG findings in complex partial status epilepticus with tiagabine [see comments].  Seizure. 1999;  8 41-44
    PubMedGoogle Scholar
  • 142 Genton P. When antiepileptic drugs aggravate epilepsy.  Brain Dev. 2000;  22 75-80
    CrossrefPubMedGoogle Scholar
  • 143 Balslev T, Uldall P, Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.  Europ J Paediatr Neurol. 2000;  4 169-170
    PubMedGoogle Scholar
  • 144 Gustavson L E, Sommerville K W, Boellner S W, Witt G F, Guenther H J, Granneman G R. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.  Am J Ther. 1998;  5 73-79
    PubMedGoogle Scholar
  • 145 Gustavson L E, Cato A, Boellner S W, Cao G X, Qian J X, Guenther H J, Sommerville K W. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.  Am J Ther. 1998;  5 9-16
    PubMedGoogle Scholar
  • 146 Datta P K, Crawford P M. Refractory epilepsy: treatment with new antiepileptic drugs.  Seizure. 2000;  9 51-57
    CrossrefPubMedGoogle Scholar
  • 147 Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, Karim R. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy.  Epilepsy Res. 1996;  25 217-224
    CrossrefPubMedGoogle Scholar
  • 148 Reife R A, Pledger G W. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials.  Epilepsia. 1997;  38 Suppl 1 S31-S33
    PubMedGoogle Scholar
  • 149 Reife R, Pledger G, Wu S C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults.  Epilepsia. 2000;  41 Suppl 1 S66-S71
    PubMedGoogle Scholar
  • 150 Svendsen T, Johannessen S I, Nakken K O. [Topiramate - a new antiepileptic agents].  Tidsskr Nor Laegeforen. 2000;  120 1536-1538
    PubMedGoogle Scholar
  • 151 Rosenfeld W E, Doose D R, Walker S A, Nayak R K. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.  Epilepsia. 1997;  38 317-323
    PubMedGoogle Scholar
  • 152 Rosenfeld W E, Doose D R, Walker S A, Baldassarre J S, Reife R A. A study of topiramate pharmacokinetics and tolerability in children with epilepsy.  Pediatr Neurol. 1999;  20 339-344
    CrossrefPubMedGoogle Scholar
  • 153 Rosenfeld W E. Topiramate: a review of preclinical, pharmacokinetic, and clinical data.  Clin Ther. 1997;  19 1294-1308
    CrossrefPubMedGoogle Scholar
  • 154 Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.  Clin Pharmacokinet. 1996;  31 29-46
    CrossrefPubMedGoogle Scholar
  • 155 Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.  Epilepsia. 1996;  37 Suppl 2 S8-S13
    PubMedGoogle Scholar
  • 156 Johannessen S I. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.  Epilepsia. 1997;  38 Suppl 1 S18-S23
    PubMedGoogle Scholar
  • 157 Glauser T A, Miles M V, Tang P, Clark P, McGee K, Doose D R. Topiramate pharmacokinetics in infants.  Epilepsia. 1999;  40 788-791
    PubMedGoogle Scholar
  • 158 Glauser T A. Topiramate.  Epilepsia. 1999;  40 Suppl 5 S71-S80
    PubMedGoogle Scholar
  • 159 Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug.  Pharmacol Res. 1997;  35 241-256
    CrossrefPubMedGoogle Scholar
  • 160 Sachdeo R C, Reife R A, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures [see comments].  Epilepsia. 1997;  38 294-300
    CrossrefPubMedGoogle Scholar
  • 161 Sachdeo R C, Glauser T A, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.  Neurology. 1999;  52 1882-1887
    PubMedGoogle Scholar
  • 162 Yang Y, Li Q, Miyashita H, Howlett W, Siddiqui M, Shuaib A. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.  J Neurosurg. 2000;  92 841-847
    PubMedGoogle Scholar
  • 163 Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.  Neuropharmacology. 2000;  39 881-888
    CrossrefPubMedGoogle Scholar
  • 164 Yang Y, Shuaib A, Li Q, Siddiqui M M. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization.  Brain Res. 1998;  804 169-176
    CrossrefPubMedGoogle Scholar
  • 165 Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000 mg daily dosages. Topiramate YE Study Group.  Neurology. 1996;  46 1678-1683
    PubMedGoogle Scholar
  • 166 Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience.  Epilepsia. 1997;  38 Suppl 1 S28-S30
    PubMedGoogle Scholar
  • 167 Sander J W. Practical aspects of the use of topiramate in patients with epilepsy.  Epilepsia. 1997;  38 Suppl 1 S56-S58
    PubMedGoogle Scholar
  • 168 Tassinari C A, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, Dam M, Reife R, Pledger G, Karim R. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy.  Epilepsia. 1996;  37 763-768
    PubMedGoogle Scholar
  • 169 Wasserstein A G, Stolley P D, Soper K A, Goldfarb S, Maislin G, Agus Z. Case-control study of risk factors for idiopathic calcium nephrolithiasis.  Miner Electrolyte Metab. 1987;  13 85-95
    PubMedGoogle Scholar
  • 170 Elterman R D, Glauser T A, Wyllie E, Reife R, Wu S C, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.  Neurology. 1999;  52 1338-1344
    CrossrefPubMedGoogle Scholar
  • 171 Ritter F, Glauser T A, Elterman R D, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.  Epilepsia. 2000;  41 Suppl 1 S82-S85
    CrossrefPubMedGoogle Scholar
  • 172 Biton V, Montouris G D, Ritter F, Riviello J J, Reife R, Lim P, Pledger G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.  Neurology. 1999;  52 1330-1337
    PubMedGoogle Scholar
  • 173 Dam M. Practical aspects of oxcarbazepine treatment.  Epilepsia. 1994;  35 Suppl 3 S23-S25
    PubMedGoogle Scholar
  • 174 Tecoma E S. Oxcarbazepine.  Epilepsia. 1999;  40 Suppl 5 S37-S46
    PubMedGoogle Scholar
  • 175 Schachter S C, Vazquez B, Fisher R S, Laxer K D, Montouris G D, Combs C D, Faught E, Willmore L J, Morris G L, Ojemann L, Bennett D, Mesenbrink P, D’Souza J, Kramer L. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures [see comments].  Neurology. 1999;  52 732-737
    PubMedGoogle Scholar
  • 176 Schachter S C, Vazquez B, Fisher R S, Laxer K D, Combs C D, Faught E, Willmore L J, Morris G L, Ojemann L, Montouris G D. Oxcarbazepine in a monotherapy trial for partial seizures - placebo-controlled studies in neurology: where do they stop? [letter].  Neurology. 1999;  53 2211-2212
    PubMedGoogle Scholar
  • 177 Bill P A, Vigonius U, Pohlmann H, Guerreiro C A, Kochen S, Saffer D, Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.  Epilepsy Res. 1997;  27 195-204
    CrossrefPubMedGoogle Scholar
  • 178 Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff B J, Brodie M J, Moore A. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.  Epilepsy Res. 1997;  26 451-460
    CrossrefPubMedGoogle Scholar
  • 179 Degen P H, Flesch G, Cardot J M, Czendlik C, Dieterle W. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.  Biopharm Drug Dispos. 1994;  15 519-526
    PubMedGoogle Scholar
  • 180 Beydoun A, Sachdeo R C, Rosenfeld W E, Krauss G L, Sessler N, Mesenbrink P, Kramer L, D’Souza J. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.  Neurology. 2000;  54 2245-2251
    CrossrefPubMedGoogle Scholar
  • 181 Larkin J G, McKee P J, Forrest G, Beastall G H, Park B K, Lowrie J I, Lloyd P, Brodie M J. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.  Br J Clin Pharmacol. 1991;  31 65-71
    PubMedGoogle Scholar
  • 182 May T W, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.  Ther Drug Monit. 1999;  21 175-181
    CrossrefPubMedGoogle Scholar
  • 183 Van-Parys J A, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis.  Epilepsy Res. 1994;  19 79-85
    CrossrefPubMedGoogle Scholar
  • 184 McKee P J, Blacklaw J, Forrest G, Gillham R A, Walker S M, Connelly D, Brodie M J. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.  Br J Clin Pharmacol. 1994;  37 27-32
    PubMedGoogle Scholar
  • 185 Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.  Epilepsia. 1994;  35 Suppl 3 S14-S19
    PubMedGoogle Scholar
  • 186 Zaccara G, Gangemi P F, Bendoni L, Menge G P, Schwabe S, Monza G C. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.  Ther Drug Monit. 1993;  15 39-42
    PubMedGoogle Scholar
  • 187 Klosterskov J P, Saano V, Haring P, Svenstrup B, Menge G P. Possible interaction between oxcarbazepine and an oral contraceptive.  Epilepsia. 1992;  33 1149-1152
    PubMedGoogle Scholar
  • 188 Fattore C, Cipolla G, Gatti G, Limido G L, Sturm Y, Bernasconi C, Perucca E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.  Epilepsia. 1999;  40 783-787
    PubMedGoogle Scholar
  • 189 Kramer G, Tettenborn B, Klosterskov J P, Menge G P, Stoll K D. Oxcarbazepine does not affect the anticoagulant activity of warfarin.  Epilepsia. 1992;  33 1145-1148
    PubMedGoogle Scholar
  • 190 Leppik I E. Antiepileptic drugs in development: prospects for the near future.  Epilepsia. 1994;  35 Suppl 4 S29-S40
    PubMedGoogle Scholar
  • 191 Glauser T A, Nigro M, Sachdeo R, Pasteris L A, Weinstein S, Abou-Khalil B, Frank L M, Grinspan A, Guarino T, Bettis D, Kerrigan J, Geoffroy G, Mandelbaum D, Jacobs T, Mesenbrink P, Kramer L, D'Souza J. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. 2000
    Google Scholar
  • 192 Schachter S C, Vazquez B, Fisher R S, Laxer K D, Montouris G D, Combs-Cantrell D T, Faught E, Willmore L J, Morris G L, Ojemann L, Bennett D, Mesenbrink P, D'Souza J, Kramer L. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. 1999
    Google Scholar
  • 193 Gaily E, Granstrom M L, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.  J Intellect Disabil Res. 1998;  42 Suppl 14 1-5
    CrossrefPubMedGoogle Scholar
  • 194 Blum D E. New drugs for persons with epilepsy.  Adv Neurol. 1998;  76 57-87
    PubMedGoogle Scholar
  • 195 Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.  Epilepsy Res. 1989;  3 70-76
    CrossrefPubMedGoogle Scholar
  • 196 Rosendahl L, Friis M L. [Metabolic encephalopathy: oxcarbazepine (Trileptal)-induced hyponatremia].  Ugeskr Laeger. 1991;  153 2637-2638
    PubMedGoogle Scholar
  • 197 Nielsen O A, Johannessen A C, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study.  Epilepsy Res. 1988;  2 269-271
    CrossrefPubMedGoogle Scholar
  • 198 Johannessen A C, Nielsen O A. Hyponatremia induced by oxcarbazepine.  Epilepsy Res. 1987;  1 155-156
    CrossrefPubMedGoogle Scholar
  • 199 Sills G J, Leach J P, Fraser C M, Forrest G, Patsalos P N, Brodie M J. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain.  Eur J Pharmacol. 1997;  325 35-40
    CrossrefPubMedGoogle Scholar
  • 200 Birnstiel S, Wulfert E, Beck S G. Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission.  Naunyn Schmiedebergs Arch Pharmacol. 1997;  356 611-618
    PubMedGoogle Scholar
  • 201 Patsalos P N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics.  Pharmacol Ther. 2000;  85 77-85
    CrossrefPubMedGoogle Scholar
  • 202 Doheny H C, Ratnaraj N, Whittington M A, Jefferys J G, Patsalos P N. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat.  Epilepsy Res. 1999;  34 161-168
    CrossrefPubMedGoogle Scholar
  • 203 Browne T R, Szabo G K, Leppik I E, Josephs E, Paz J, Baltes E, Jensen C M. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique.  J Clin Pharmacol. 2000;  40 590-595
    CrossrefPubMedGoogle Scholar
  • 204 Grant R, Shorvon S D. Efficacy and tolerability of 1000 - 4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.  Epilepsy Res. 2000;  42 89-95
    CrossrefPubMedGoogle Scholar
  • 205 Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.  Epilepsia. 2000;  41 1276-1283
    CrossrefPubMedGoogle Scholar
  • 206 Shorvon S D, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.  Epilepsia. 2000;  41 1179-1186
    PubMedGoogle Scholar
  • 207 Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.  Eur J Pharmacol. 2000;  391 251-254
    CrossrefPubMedGoogle Scholar
  • 208 Nicolas J M, Collart P, Gerin B, Mather G, Trager W, Levy R, Roba J. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent.  Drug Metab Dispos. 1999;  27 250-254
    PubMedGoogle Scholar
  • 209 Cereghino J J, Biton V, Abou K B, Dreifuss F, Gauer L J, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.  Neurology. 2000;  55 236-242
    PubMedGoogle Scholar
  • 210 Cramer J A, Arrigo C, Van-Hammee G, Gauer L J, Cereghino J J. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.  Epilepsia. 2000;  41 868-874
    PubMedGoogle Scholar
  • 211 Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.  Seizure. 2000;  9 80-87
    CrossrefPubMedGoogle Scholar
  • 212 Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.  J Pharmacol Exp Ther. 1998;  284 474-479
    PubMedGoogle Scholar
  • 213 Loscher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats.  Epilepsy Res. 2000;  40 63-77
    CrossrefPubMedGoogle Scholar
  • 214 Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.  Eur J Pharmacol. 1998;  353 191-206
    CrossrefPubMedGoogle Scholar
  • 215 Stefan H, Froscher W, Kramer G, Schmidt D. Pharmakotherapie vor und nach epilepsiechirurgischen Eingriffen. Ein kritischer Uberblick und Empfehlungen. [Drug therapy before and after surgery for epilepsy. Critical review and recommendations].  Nervenarzt. 2000;  71 451-458
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. H. Stefan

Neurologische Klinik - Zentrum Epilepsie (ZEE) Universität Erlangen-Nürnberg

Schwabachanlage 6

91054 Erlangen

      >